中文 | English
 
毛斐
发布时间：2018-10-22   访问次数:8519   作者:毛斐





毛斐，博士，副教授

地址：梅陇路130号实验18楼431室

Email：maofei@ecust.edu.cn

 

个人简介

2014年6月毕业于中山大学raybet雷竞技竞猜在线官网药物化学专业，获博士学位，后进入raybet雷竞技竞猜在线官网从事博士后研究，合作导师为李剑教授。2016年10月出站后留校工作，从事药物化学教学和科研工作，2018年9月晋升副教授。

作为项目负责人，先后主持国家自然科学基金青年基金1项、面上项目1项、上海市自然科学基金面上项目1项、博士后科学基金（面上一等资助）1项、教育部高校基本科研业务费1项；2017年入选上海市“青年科技英才扬帆计划”；2018年入选raybet雷竞技竞猜在线官网“青年英才培育计划”A类；作为研究骨干参与国家新药创制重大专项1项，国家重点研发计划课题1项。

迄今已在国内外重要刊物如Adv. Sci., J. Med. Chem., Eur. J. Med. Chem., Cell Death Dis., ACS Chem. Neurosci.等上发表SCI论文60余篇；申请发明专利32项，授权19项（包括国外专利5项）；参编《药物结构优化—设计策略和经验规则》论著和国家一流本科课程教材《药物化学》。


教育经历

2009.9 – 2014.6，中山大学，raybet雷竞技竞猜在线官网，药物化学，博士；

2005.8 – 2009.6，沈阳药科大学，制药工程学院，应用化学，学士。

工作经历

2018.9 – 至今，raybet雷竞技竞猜在线官网，raybet雷竞技竞猜在线官网，副教授；

2016.11 – 2018.8，raybet雷竞技竞猜在线官网，raybet雷竞技竞猜在线官网，讲师；

2014.7 – 2016.10，raybet雷竞技竞猜在线官网，raybet雷竞技竞猜在线官网，师资博士后。

  

主要研究方向

  1. 抗肿瘤创新药物开发研究

  2. 抗耐药菌创新药物开发研究

  3. 老药二次开发研究  

  

代表性论文 (#共同第一作者，*为通讯作者)

  1. Qi Wang#, Lijuan Li#, Xiaoyan Gao#, Chunxue Zhang, Chen Xu, Lingyi Song, Jian Li, Xiao Sun*, Fei Mao*, Yudong Wang*. Targeting GRP75 with a Chlorpromazine Derivative Inhibits Endometrial Cancer Progression Through GRP75–IP3R-Ca2+-AMPK Axis. Adv. Sci. 2024, 11, 2304203.

  2.  Lijuan Li#, Xiaohu Liu#, Yunxia Cui, Yang Chen, Huiwen Wu, Jing Wang, Xiaodi Gong, Xiaoyan Gao, Linlin Yang, Jian Li, Xiao Sun*, Fei Mao*, Yudong Wang*. Novel chlorpromazine derivatives as anti-endometrial carcinoma agents with reduced extrapyramidal side effects. Bioorg. Chem. 2022, 127, 106008. doi: 10.1016/j.bioorg.2022.106008.

  3. Keting Bao#, Yongyun Li#, Jinlian Wei#, Ruoxi Li, Jie Yang, Jiahao Shi, Baoli Li, Jin Zhu, Fei Mao*, Renbing Jia*, Jian Li*. Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway. Cell Death Dis. 2021, 12, 380.

  4. Yunxia Cui, Huiwen Wu, Linlin Yang, Ting Huang, Jian Li, Xiaodi Gong, Lijuan Li, Xiao Sun*, Fei Mao*, Yudong Wang*. Chlorpromazine sensitizes progestin-resistant endometrial cancer cells to MPA by upregulating PRB. Front. Oncol. 2021, 11, 665832.

  5. Linghao Hu#, Hongxuan Feng#,Hongguang Zhang, Songda Yu, Qinyuan Zhao, Wei Wang, Fengxia Bao, Xun Ding, Jiajing Hu, Manjiong Wang, Yixiang Xu, Zengrui Wu, Xiaokang Li, Yun Tang, Fei Mao*, Xiaoyan Chen, Haiyan Zhang*, Jian Li*. Development of Novel N-hydroxypyridone Derivatives as Potential Anti-Ischemic Stroke Agents. J. Med. Chem. 2020, 63, 1051-1067.

  6.  Yang Chen#, Yunxia Cui#, Xiao Sun#, Huiwen Wu, Manjiao Ou, Yunzhe Tang, Shuaishuai Ni, Xiaokang Li, Jin Zhu, Fei Mao*, Yudong Wang* and Jian Li*. Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer. Bioorg. Med. Chem Lett. 2020, 30, 127239.

  7. Wenwen Liu#, Huan Wang#, Xiaokang Li#, Yixiang Xu, Jian Zhang, Wei Wang, Qi Gong, Xiaoxia Qiu, Jin Zhu, Fei Mao*, Haiyan Zhang*, Jian Li*. Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment. Bioorg. Med. Chem. 2018, 26, 3117–3125.

  8. Wei Ni#, Huan Wang#, Xiaokang Li#, Xinyu Zheng#, Manjiong Wang, Jian Zhang, Qi Gong, Dazheng Ling, Fei Mao*, Haiyan Zhang*, Jian Li*. Novel tadalafil derivatives ameliorates scopolamine-induced cognitive impairment in mice via inhibition of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5). ACS Chem. Neurosci. 2018, 9, 1625–1636.

  9. Baoli Li#, Shuaishuai Ni#, Fei Mao#, Feifei Chen, Yifu Liu, Hanwen Wei, Wenhua Chen, Jin Zhu, Lefu Lan*, Jian Li*. Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity. J. Med. Chem. 2018, 61, 224–250.

  10. Fei Mao#, Huan Wang#, Wei Ni#, Xinyu Zheng, Manjiong Wang, Keting Bao, Dazheng Ling, Xiaokang Li, Yixiang Xu, Haiyan Zhang*, Jian Li*. Design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5) for the treatment of Alzheimer’s disease. ACS Chem. Neurosci. 2018, 9, 328–345.

  11. Hanwen Wei#, Fei Mao#, Shuaishuai Ni#, Feifei Chen, Baoli Li, Xiaoxia Qiu, Linghao Hu, Manjiong Wang, Xinyu Zheng, Jin Zhu, Lefu Lan*, Jian Li*. Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections. Eur. J. Med. Chem. 2018, 145, 235–251.

  12. Yi-xiang Xu#, Huan Wang#, Xiao-kang Li, Sheng-nan Dong, Wen-wen Liu, Qi Gong, Tian-duan-yi Wang, Yun Tang, Jin Zhu, Jian Li*, Hai-yan Zhang*, Fei Mao*. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2018, 143, 33–47.

  13. Xiaokang Li#, Huan Wang#, Yixiang Xu, Wenwen Liu, Xiaoxia Qiu, Jin Zhu, Fei Mao*, Haiyan Zhang*, Jian Li*. Novel vilazodone-tacrine hybrids as potential multitarget-directed ligands for the treatment of Alzheimer’s disease accompanied with depression: design, synthesis and biological evaluation. ACS Chem. Neurosci. 2017, 8, 2708–2721.

  14. Yanli Lu#, Fei Mao#, Xiaokang Li, Xinyu Zheng, Manjiong Wang, Qing Xu, Jin Zhu, and Jian Li*. Discovery of potent, selective stem cell factor receptor/platelet derived growth factor receptor alpha (c-KIT/PDGFRα) dual inhibitor for the treatment of imatinib-resistant gastrointestinal stromal tumors (GISTs). J. Med. Chem. 2017, 60, 5099–5119.

  15. Xiaokang Li#, Huan Wang#, Zhengyu Lu, Xinyu Zheng, Wei Ni, Jin Zhu, Yan Fu, Fulin Lian, Naixia Zhang, Jian Li*, Haiyan Zhang*, and Fei Mao*. Development of multifunctional pyrimidinylthiourea derivatives as potential anti-Alzheimer agents. J. Med. Chem. 2016, 59, 8326−8344.

  16. Dengwei Wu#, Fei Mao#, Yan Ye, Jian Li, Chuanlian Xu*, Xiaomin Luo, Jing Chen*, Xu Shen. Policresulen as a novel inhibitor of NS2B/NS3 protease efficiently suppressed the replication of DENV2 virus. Acta Pharmacol. Sin. 2015, 36, 1126-1136.

  17. Fei Mao, Jianheng Li, Hui Wei, Ling Huang*, Xingshu Li*. Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease. J. Enzym. Inhib. Med. Chem.2015,30, 995-1001.

  18. Fei Mao, Jun Yan, Jian-heng Li, Yang sun, Xian Jia, Ling Huang*, Xing-shu Li*. New Multi-Target-Directed Small Molecules Against Alzheimer's Disease: a Combination of Resveratrol and Clioquinol. Org. Biomol. Chem. 2014, 12, 5936-5944.

  19. Fei Mao, Jian-wen Chen*, Qi Zhou, Zong-hua Luo, Li Huang, Xing-shu Li*. Novel tacrine–ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity. Bioorg. Med. Chem. Lett.2013, 23, 6737-6742.

  20. Fei Mao, Ling Huang, Zong-hua Luo, Anqiu Liu, Chuan-jun Lu, Zhi-yong Xie*, Xingshu Li*. O-Hydroxyl or o-amino benzylamine-tacrine hybrids: Multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-beta aggregation. Bioorgan. Med. Chem.2012, 20, 5884-5892.